Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC

NCT07050056 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Resectable NSCLC

Interventions

DRUG: Tislelizumab
RADIATION: 3D-CRT/IMRT

Sponsor

Northern Jiangsu People's Hospital